Prostatitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRS047 MIFTS: 60	Prostatitis Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis ¹² ⁷⁶ ⁵⁵ ⁴⁴ ¹⁵ ⁷³

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the genitourinary system

Diseases of male genital organs

Inflammatory diseases of prostate

Inflammatory disease of prostate, unspecified

External Ids:

Disease Ontology ¹² DOID:14654

ICD10 ³³ N41 N41.9

ICD9CM ³⁵ 601 601.9

MeSH ⁴⁴ D011472

NCIt ⁵⁰ C26866

SNOMED-CT ⁶⁸ 155907007 155911001 197962006 more

UMLS ⁷³ C0033581

Sources

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostate sarcoma and prostate cancer, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : ⁷⁶ Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Sources

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 966)

#	Related Disease	Score	Top Affiliating Genes
1	prostate sarcoma	34.6	KLK3 NKX3-1
2	prostate cancer	33.3	KLK3 MSMB NKX3-1 PROS1 TGFB1 VDR
3	chronic kidney failure	31.8	IL6 TGFB1 VDR
4	kaposi sarcoma	30.9	CXCL8 IL6 TNF
5	alpha-2-macroglobulin deficiency	30.2	KLK3 PROS1
6	breast disease	30.1	KLK3 TGFB1 TNF
7	spinal cord injury	30.1	IL6 TGFB1 TNF
8	cystitis	30.0	CXCL8 IL6 TNF
9	choroiditis	29.8	IL10 TNF
10	posterior urethral valves	29.7	IL6 TGFB1 TNF
11	oral tuberculosis	29.6	IL2 TNF
12	conjunctivitis	29.6	CXCL8 IL2 IL6
13	microscopic polyangiitis	29.5	IL10 TNF
14	osteoarthritis	29.5	IL1B IL6 TGFB1 TNF
15	melioidosis	29.3	IL10 IL6 TNF
16	fasciitis	29.3	CXCL8 IL6 TNF
17	pouchitis	29.1	CXCL8 IL10
18	exanthem	29.0	IL2 IL6 TNF
19	obstructive jaundice	29.0	CXCL8 IL6 TNF
20	acute pyelonephritis	29.0	CXCL8 IL10 IL6
21	necrotizing fasciitis	29.0	CXCL8 IL2 IL6
22	myeloma, multiple	28.9	CXCL8 IL2 IL6 TNF
23	esophagitis	28.9	CXCL8 IL1B IL6
24	schistosomiasis	28.9	IL10 IL2 TNF
25	echinococcosis	28.9	IL10 IL6 TNF
26	reactive arthritis	28.8	IL10 IL6 TNF
27	vaginitis	28.8	CXCL8 IL1B IL6
28	pulmonary tuberculosis	28.8	IL10 IL2 TNF VDR
29	arteries, anomalies of	28.6	IL1B IL6 TNF
30	laryngitis	28.5	IL1B IL6 TGFB1 TNF
31	paracoccidioidomycosis	28.5	IL10 IL2 IL6 TNF
32	fatty liver disease	28.5	IL1B IL6 TNF
33	myasthenia gravis	28.4	IL10 IL2 TNF
34	osteoporosis	28.3	IL1B IL6 TGFB1 TNF VDR
35	bone disease	28.3	IL1B IL6 TNF VDR
36	endocarditis	28.2	CXCL8 IL10 IL6 TNF
37	haemophilus influenzae	28.2	CXCL8 IL1B TNF
38	periodontal disease	28.1	CXCL8 IL1B IL6 TNF
39	filariasis	28.0	IL10 IL2 IL6 TNF
40	osteomyelitis	28.0	CXCL8 IL1B IL6 TNF
41	alcoholic hepatitis	28.0	CXCL8 IL10 IL6 TNF
42	wegener granulomatosis	28.0	CXCL8 IL10 IL6 TNF
43	q fever	28.0	IL10 IL1B TNF
44	synovitis	27.9	CXCL8 IL1B IL6 TNF
45	leishmaniasis	27.8	IL10 IL1B TNF
46	human immunodeficiency virus type 1	27.8	IL10 IL2 IL6 TNF
47	gingivitis	27.7	CXCL8 IL1B IL6 TNF
48	monocytic leukemia	27.6	CXCL8 IL1B IL6 TNF
49	pulmonary fibrosis, idiopathic	27.6	CXCL8 IL1B TGFB1 TNF
50	chlamydia	27.4	CXCL8 IL10 IL1B IL6 TNF

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):

Acute Cystitis	Bladder Neck Obstruction
Chronic Myocardial Ischemia	Epididymo-Orchitis
Ischemic Heart Disease	Prostate Calculus
Prostate Cancer	Prostatic Hypertrophy
Urethral Stricture	Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:

Sources

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:

prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.77	TGFB1 TNF ADRA1A CXCL8 IL10 IL1B
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.77	TGFB1 TNF ADRA1A CXCL8 IL10 IL1B

MGI Mouse Phenotypes related to Prostatitis:

⁴⁶ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.16	IL1B IL2 PROS1 ADRA1A IL6 IL10
2	homeostasis/metabolism	MP:0005376	10.13	IL10 IL1B NKX3-1 IL2 ADRA1A IL6
3	endocrine/exocrine gland	MP:0005379	10.08	MSMB NKX3-1 IL2 IL6 IL10 TNF
4	hematopoietic system	MP:0005397	10.06	IL6 IL10 IL1B IL2 TNF PROS1
5	digestive/alimentary	MP:0005381	10.04	NKX3-1 IL2 IL6 IL10 VDR TGFB1
6	mortality/aging	MP:0010768	10.02	IL6 IL10 IL1B NKX3-1 IL2 ADRA1A
7	integument	MP:0010771	9.95	IL6 IL10 IL1B TNF PROS1 VDR
8	liver/biliary system	MP:0005370	9.85	IL6 IL10 IL2 TNF PROS1 TGFB1
9	muscle	MP:0005369	9.8	PROS1 ADRA1A IL6 IL10 TNF VDR
10	neoplasm	MP:0002006	9.76	MSMB IL1B NKX3-1 IL2 IL6 IL10
11	reproductive system	MP:0005389	9.56	MSMB NKX3-1 IL2 IL6 IL10 TNF
12	skeleton	MP:0005390	9.17	IL6 IL10 IL1B NKX3-1 TNF VDR

Sources

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetaminophen

Approved

Phase 4

103-90-2

1983

Cycloserine

Approved

Phase 4,Phase 3

68-41-7

401 6234

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone

Approved, Investigational

Phase 4

58-22-0

6013

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

Acetylcholine

Approved

Phase 4,Phase 3,Phase 2

51-84-3

187

Ciprofloxacin

Approved, Investigational

Phase 4,Phase 3

85721-33-1

2764

Tadalafil

Approved, Investigational

Phase 4

171596-29-5

110635

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Fosfomycin

Approved

Phase 4

23155-02-4

446987

Sulfamethoxazole

Approved

Phase 4

723-46-6

5329

Trimethoprim

Approved, Vet_approved

Phase 4

738-70-5

5578

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

gamma-Aminobutyric acid

Approved, Investigational

Phase 4

56-12-2

119

Cefotaxime

Approved

Phase 4

63527-52-6

456256 5742673

Cefoxitin

Approved

Phase 4

35607-66-0

441199

Cilastatin

Approved, Investigational

Phase 4

82009-34-5

5280454 6435415

Imipenem

Approved

Phase 4

74431-23-5, 64221-86-9

104838

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 4

58-05-9

143 6006

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Prulifloxacin

Investigational

Phase 4,Phase 2

123447-62-1

Cholinergic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2

Analgesics

Phase 4,Phase 3,Phase 2

Anti-Anxiety Agents

Phase 4,Phase 3

Anticonvulsants

Phase 4,Phase 3

calcium channel blockers

Phase 4,Phase 3

Calcium, Dietary

Phase 4,Phase 3,Phase 2

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Phase 1

Psychotropic Drugs

Phase 4,Phase 3

Tranquilizing Agents

Phase 4,Phase 3

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1

Antitubercular Agents

Phase 4,Phase 3

Fluoroquinolones

Phase 4,Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 4,Phase 3,Phase 2

Permixon

Phase 4,Phase 3

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2

Antimetabolites

Phase 4,Phase 3

Renal Agents

Phase 4,Phase 3,Phase 2

Anabolic Agents

Phase 4

Androgens

Phase 4,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4

Hormone Antagonists

Phase 4,Phase 3,Early Phase 1

Hormones

Phase 4,Phase 3,Early Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 79)

#	Name	Status	NCT ID	Phase	Drugs
1	Treatment of Chronic Bacterial Prostatitis	Completed	NCT02130713	Phase 4	Third generation fluoroquinolone
2	Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain	Completed	NCT02385266	Phase 4	D-Cycloserine;Placebo (for D-cycloserine)
3	TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST	Completed	NCT02366975	Phase 4	Testosterone gel 2%
4	Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication	Completed	NCT02246361	Phase 4
5	Botox as a Treatment for Interstitial Cystitis in Women	Completed	NCT00194610	Phase 4	Botox
6	Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms	Recruiting	NCT02252367	Phase 4	Tadalafil
7	Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.	Not yet recruiting	NCT03228108	Phase 4	Ciprofloxacin;Trimethoprim/Sulfamethoxazole;Fosfomycin;Pivmecillinam/augmentin
8	Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)	Suspended	NCT00194636	Phase 4
9	Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III	Terminated	NCT00194597	Phase 4	Viagra (sildenafil citrate)
10	Botox as a Treatment for Chronic Male Pelvic Pain Syndrome	Terminated	NCT00194623	Phase 4	Botulinum Toxin A (Botox)
11	Efficacy of Gralise® for Chronic Pelvic Pain	Terminated	NCT01678911	Phase 4	Gralise
12	Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli	Terminated	NCT02474706	Phase 4	Cefoxitin;imipenem
13	Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Unknown status	NCT00371033	Phase 3	Pregabalin;Placebo
14	Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)	Completed	NCT00919893	Phase 3	Cernilton;Placebo
15	Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis	Completed	NCT00260637	Phase 2, Phase 3
16	An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis	Completed	NCT00402688	Phase 3	levofloxacin;levofloxacin;levofloxacin
17	A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis	Completed	NCT00236808	Phase 3	levofloxacin
18	Levofloxacin, Chronic Bacterial Prostatitis	Completed	NCT00277511	Phase 3	Levofloxacin
19	Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Completed	NCT00103402	Phase 3	Alfuzosin
20	Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)	Completed	NCT00169585	Phase 3	Levofloxacin oral tablets
21	Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)	Completed	NCT00495651	Phase 3	Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
22	Complementary and Alternative Medicine for Urological Symptoms(CAMUS)	Completed	NCT00603304	Phase 3	Saw Palmetto - first 24 weeks;Placebo - first 24 weeks;Saw Palmetto - weeks 24 - 48;Placebo - weeks 24 - 48;Saw Palmetto - weeks 48 - 72;Placebo - weeks 48 - 72
23	"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk	Completed	NCT00056407	Phase 3	Dutasteride;Placebo
24	Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment	Completed	NCT00090103	Phase 3	dutasteride 0.5mg once daily for 4 years;tamsulosin 0.4mg once daily for 4 years
25	JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Terminated	NCT01830829	Phase 3	Jalyn;Placebo
26	Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome	Terminated	NCT00464373	Phase 3	Botulinum Toxin Type A;Placebo
27	Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin	Withdrawn	NCT02975570	Phase 3	Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
28	Laparoscopic Prostatectomy for Chronic Prostatitis	Unknown status	NCT00775515	Phase 2
29	Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.	Completed	NCT00740779	Phase 2	Silodosin 8 mg;Placebo;Silodosin 4 mg
30	An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Completed	NCT00701311	Phase 2	CC-10004
31	Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Completed	NCT00529386	Phase 2	Botox;Lidocaine
32	An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis	Completed	NCT00826514	Phase 2	Tanezumab;Placebo
33	An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland	Completed	NCT00236990	Phase 2	pentosan polysulfate sodium
34	A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)	Completed	NCT01391338	Phase 2	ASP3652;Placebo
35	A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome	Completed	NCT00362752	Phase 2	Norfloxacin;Placebo
36	Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder	Completed	NCT00343356	Phase 2	Trement
37	Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)	Completed	NCT00037141	Phase 1, Phase 2	dehydrated alcohol
38	Prulifloxacin in Chronic Bacterial Prostatitis (CBP)	Recruiting	NCT03201796	Phase 2	Prulifloxacin 600 mg;Levofloxacin 500mg
39	Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Recruiting	NCT03500159	Phase 2	AQX-1125 200 mg;Placebo
40	Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy	Recruiting	NCT02961114	Phase 1, Phase 2
41	Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain	Terminated	NCT00301405	Phase 2	Thalidomide
42	Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis	Unknown status	NCT00913315	Not Applicable	tolterodine;tamsulosin;placebo
43	Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome	Unknown status	NCT01714830	Not Applicable
44	Shocking Therapy for Chronic Pelvic Pain Syndrome	Unknown status	NCT01828996	Not Applicable
45	Effect of Pumpkin Seeds Phonophoresis on Chronic Non-bacterial Prostatitis	Completed	NCT03461263	Not Applicable
46	Non Interventional Study of Levofloxacin in Chronic Prostatitis	Completed	NCT02711943		Levofloxacin 500
47	Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome	Completed	NCT00922012	Not Applicable
48	Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome	Completed	NCT01826617
49	Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Completed	NCT01843946
50	Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis	Completed	NCT01098279

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

ciprofloxacin

Cochrane evidence based reviews: prostatitis

Sources

Genetic Tests for Prostatitis

Sources

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

⁴¹

Prostate, Bone, Endothelial, Lymph Node, Testes, Lung, T Cells

Sources

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 27530)

#	Title	Authors	Year
1	Ga-68-PSMA PET/CT in treatment-naA^ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases? ( 29978529 )	Rogasch J.M....Baur A.D.J.	2018
2	Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )	Liang W....Dai S.	2018
3	Effect of Essential Oil on Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Randomized Controlled Trial. ( 29948596 )	Ying J....Zhang Z.J.	2018
4	Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males. ( 29947032 )	Lu J.C....Yao B.	2018
5	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. ( 29975957 )	Porcaro A.B....Artibani W.	2018
6	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. ( 29978216 )	Autio K.A....Scher H.I.	2018
7	Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade. ( 29731795 )	Saffar H....Azimi S.	2018
8	Chronic reactive arthritis associated with prostatitis caused by<i>Neisseria meningitidis</i>. ( 29374652 )	Kawahara K....Morita Y.	2018
9	Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )	Mohsenzadegan M....Khoshmirsafa M.	2018
10	PPARI' Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. ( 29187400 )	MartA-n-MartA-n N....Carracedo A.	2018
11	Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( 28624553 )	Kwon S.Y....Yun S.J.	2018
12	Guided undersampling classification for automated radiation therapy quality assurance of prostate cancer treatment. ( 29377156 )	Brown W.E....McIntosh C.J.	2018
13	Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )	Pham H....Sharma P.	2018
14	Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )	Li W....Xia P.	2018
15	Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. ( 29293372 )	Denis-Bacelar A.M....Flux G.D.	2018
16	Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. ( 29979319 )	Rescigno P....de Bono J.	2018
17	Management of chronic prostatitis/chronic pelvic pain syndrome. ( 29875042 )	Doiron R.C....Nickel J.C.	2018
18	Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. ( 27998647 )	Di Sebastiano K.M....Mourtzakis M.	2018
19	Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. ( 29977602 )	Ebhardt H.A....Aebersold R.	2018
20	68Ga-PSMA-HBED-CC-Avid Synchronous Urinary Bladder Paraganglioma in a Patient With Metastatic Prostate Carcinoma. ( 29916916 )	Parihar A.S....Singh S.K.	2018
21	A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. ( 29981500 )	Mamouni K....Wu D.	2018
22	PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. ( 28924059 )	Kao K.R....Popadiuk C.	2018
23	Prostatic cyst in general practice: A case report and literature review. ( 29489699 )	Qiu Y....Ren J.	2018
24	Informational needs during active surveillance for prostate cancer: A qualitative study. ( 28886974 )	Loeb S....Sedlander E.	2018
25	Heteronormativity and prostate cancer: A discursive paper. ( 28382781 )	Kelly D....Vougioukalou S.	2018
26	Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study. ( 28710845 )	Porpiglia F....Geuna S.	2018
27	TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. ( 29449534 )	Liang C....Wang Z.	2018
28	Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup>Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. ( 29358059 )	Rauscher I....Eiber M.	2018
29	Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. ( 29254781 )	Yang D.D....Orio P.F.	2018
30	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. ( 29980832 )	Afshar-Oromieh A....Haberkorn U.	2018
31	Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. ( 29324665 )	Wang Y....Xu G.	2018
32	Oncostatin M induces tumorigenic properties in non-transformed human prostate epithelial cells, in part through activation of signal transducer and activator of transcription 3 (STAT3). ( 29526757 )	Sterbova S....Persson E.	2018
33	Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. ( 29138344 )	Zhang W....Thompson T.C.	2018
34	FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X<sub>L</sub> cell survival genes. ( 29357840 )	Maciel-Silva P....Garay-Malpartida H.M.	2018
35	The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative. ( 29978558 )	Pak S....Ahn H.	2018
36	Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer. ( 28786220 )	Wu F.J....Chung S.D.	2018
37	Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN<sup>-/-</sup>/p53<sup>-/-</sup>Prostate Cancer Cells In Vitro and Ex Vivo. ( 28578487 )	Pan H....Lin H.S.	2018
38	Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. ( 29129687 )	Mi Y....Xia G.	2018
39	Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. ( 29150561 )	Belderbos B.P.S....Mathijssen R.H.J.	2018
40	New prostate cancer grade grouping system predicts survival after radical prostatectomy. ( 29447924 )	Erickson A....Mirtti T.	2018
41	Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing? ( 29962733 )	Arora S....Arun Raj S.T.	2018
42	Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer. ( 29980839 )	de Oliveira Barros E.G....Palumbo A.	2018
43	The Impact of<sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. ( 28646014 )	Roach P.J....Scott A.M.	2018
44	Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )	Ekanayake S.K.D.M....Lee J.C.	2018
45	Involvement of prostatic interstitial cells of Cajal in inflammatory cytokines-elicited catecholamines production: Implications for the pathophysiology of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). ( 29649477 )	Wang J....Wang Q.	2018
46	Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases. ( 29633789 )	Toth A....Zhang J.C.	2018
47	Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study. ( 29680006 )	Abdel-Meguid T.A....Abdelsalam A.	2018
48	Tardive Dyskinesia: Is Vitamin E Singing the Prostate Blues? ( 29701932 )	Deardorff O.G....Hunter D.R.	2018
49	Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )	Schoenthaler M....Wilhelm K.	2018
50	Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome. ( 29541472 )	Bhangoo M.S....Kosty M.P.	2018

Sources

Genes for Prostatitis

Genes related to Prostatitis (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KLK3	Kallikrein Related Peptidase 3	Protein Coding	38.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11025702 8854063 9471136 (more) 7519804 15548444 12699471 1372427 19936177 1372426 7518599 15264238 17159365 7686714 10559617 19570492 16209120 12544313 15693428 15638019 12890953 16401916 17318358 17111077 8791046 15241826 15636686 8821701 19548108 16502048 15947609 19725275 15190652 1697014 9687990 7509526 1279213 10799250 1707989 20177031 19111800 18336465 16630522 10604330 7526771 1372788 20224265 15852679 9599634 9126226 9111601 1283895 19524944 18668524 18362491 16800738 16890703 15018076 12913688 11641977 10216506 8750649 1690092 19603556 18836536 18380989 17695414 16882055 14515754 20096883 18595241 17637759 15716187 12962896 10765070 19269787 14770085 11223671 11186419 7533474 9352130 20448364 14624908 15993362 14504750 11225437 7544204
2	VDR	Vitamin D Receptor	Protein Coding	24.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19269787 17142748 18594491 (more) 17241782
3	MSMB	Microseminoprotein Beta	Protein Coding	24.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	PROS1	Protein S	Protein Coding	23.79	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20450358 15389786
5	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	23.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	IL6	Interleukin 6	Protein Coding	23.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	NKX3-1	NK3 Homeobox 1	Protein Coding	23.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	IL1B	Interleukin 1 Beta	Protein Coding	22.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	TNF	Tumor Necrosis Factor	Protein Coding	22.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	IL10	Interleukin 10	Protein Coding	22.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	ADRA1A	Adrenoceptor Alpha 1A	Protein Coding	22.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	IL2	Interleukin 2	Protein Coding	21.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	21.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Prostatitis

Sources

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Sources

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)

#	Super pathways	Score	Top Affiliating Genes
1	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.62	CXCL8 IL10 IL1B IL2 IL6 TGFB1
2	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.48	CXCL8 IL10 IL1B IL2 IL6 TGFB1
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.39	CXCL8 IL10 IL1B IL2 IL6 TGFB1
4	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.33	CXCL8 IL10 IL1B IL2 IL6 TGFB1
5	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.28	CXCL8 IL10 IL1B IL2 IL6 TGFB1
6	Toll-like Receptor Signaling Pathway ³⁷ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁷ NOD-like receptor signaling pathway ³⁷ NOD-like Receptor Signaling Pathways ⁶⁵ Regulation of toll-like receptor signaling pathway ¹	13.03	CXCL8 IL10 IL1B IL2 IL6 TGFB1
7	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.9	CXCL8 IL10 IL1B IL2 IL6 TGFB1
8	Pathways in cancer ³⁷	12.85	CXCL8 IL2 IL6 KLK3 NKX3-1 TGFB1
9	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.79	CXCL8 IL1B IL2 IL6 TNF
10	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.7	IL1B IL2 IL6 TGFB1 TNF
11	Regulation of IFNA signaling ⁶⁶ Show member pathways Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Jak-STAT signaling pathway ³⁷	12.66	CXCL8 IL10 IL1B IL2 IL6 TNF
12	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.6	IL10 IL1B IL2 IL6 TNF
13	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.55	CXCL8 IL6 TGFB1 TNF
14	NF-kappaB Signaling ⁴	12.54	IL10 IL1B IL2 TNF
15	Th17 cell differentiation ³⁷ Show member pathways Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.47	IL10 IL1B IL2 IL6 TGFB1 TNF
16	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.44	IL10 IL1B IL2 IL6 TGFB1 TNF
17	HTLV-I infection ³⁷	12.42	IL2 IL6 TGFB1 TNF
18	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.34	IL1B IL2 IL6 TNF
19	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁷ Interleukin-17 signaling ⁶⁶ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.34	CXCL8 IL1B IL6 TNF
20	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.28	CXCL8 IL1B IL6 TNF
21	Toxoplasmosis ³⁷ Show member pathways Leishmaniasis ³⁷	12.27	IL10 IL1B TGFB1 TNF
22	C-type lectin receptor signaling pathway ³⁷ Show member pathways Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.26	IL10 IL1B IL2 IL6 TNF
23	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ IL-6-type cytokine receptor ligand interactions ⁶⁶ Interleukin-6 family signaling ⁶⁶ Interleukin-6 signaling ⁶⁶ Th17 Differentiation Pathway ⁶⁵	12.26	IL10 IL1B IL2 IL6 TGFB1 TNF
24	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways Immune response IL-1 signaling pathway ²² Mucin expression in CF via TLRs, EGFR signaling pathways ²²	12.23	CXCL8 IL1B IL6 TNF
25	Tuberculosis ³⁷	12.22	IL10 IL1B IL6 TGFB1 TNF VDR
26	Bacterial infections in CF airways ²² Show member pathways IL-1 beta-dependent CFTR expression ²² Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²²	12.2	CXCL8 IL1B IL6 TNF
27	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	12.12	CXCL8 IL10 IL1B IL2 IL6 TGFB1
28	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.12	CXCL8 IL10 IL1B IL6 NKX3-1 TNF
29	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.08	IL6 KLK3 TGFB1
30	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.05	IL10 IL6 TGFB1
31	Adipogenesis ¹	12.03	IL6 TGFB1 TNF
32	Osteoclast differentiation ³⁷	12.02	IL1B TGFB1 TNF
33	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	12.02	IL10 IL2 IL6 TNF
34	Senescence and Autophagy in Cancer ¹	11.98	CXCL8 IL1B IL6 TGFB1
35	TNF signaling pathway ³⁷	11.94	IL1B IL6 TNF
36	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.94	CXCL8 IL1B IL6 TGFB1 TNF
37	Spinal Cord Injury ¹	11.92	CXCL8 IL1B IL2 IL6 TGFB1 TNF
38	Hematopoietic cell lineage ³⁷	11.89	IL1B IL6 TNF
39	Rheumatoid arthritis ³⁷	11.89	CXCL8 IL1B IL6 TGFB1 TNF
40	NF-kappa B signaling pathway ³⁷	11.88	CXCL8 IL1B TNF
41	Corticotropin-releasing hormone signaling pathway ¹	11.87	CXCL8 IL2 TGFB1
42	Jak-Stat Signaling Pathway ⁶⁷	11.86	IL10 IL2 IL6
43	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.86	CXCL8 IL6 TGFB1
44	Interleukin-4 and 13 signaling ⁶⁶	11.86	CXCL8 IL10 IL1B IL6 TGFB1 TNF
45	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.85	IL10 IL1B IL2 TNF
46	Salmonella infection (KEGG) ³⁷	11.83	CXCL8 IL1B IL6
47	Glucocorticoid receptor regulatory network ¹	11.81	CXCL8 IL2 IL6
48	Pertussis ³⁷	11.8	CXCL8 IL10 IL1B IL6 TNF
49	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ¹	11.77	CXCL8 IL2 TNF
50	Amoebiasis ³⁷	11.72	CXCL8 IL10 IL1B IL6 TGFB1 TNF

Sources

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.65	CXCL8 IL10 IL1B IL2 IL6 KLK3
2	secretory granule	GO:0030141	9.33	IL1B KLK3 TGFB1
3	extracellular space	GO:0005615	9.32	CXCL8 IL10 IL1B IL2 IL6 KLK3

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show all 50)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	9.99	CXCL8 IL10 IL1B IL2 IL6 TNF
2	MAPK cascade	GO:0000165	9.97	IL1B IL2 TGFB1 TNF
3	inflammatory response	GO:0006954	9.95	CXCL8 IL10 IL1B IL6 TGFB1 TNF
4	leukocyte migration	GO:0050900	9.93	IL1B PROS1 TGFB1 TNF
5	positive regulation of gene expression	GO:0010628	9.93	IL1B IL6 NKX3-1 TGFB1 TNF VDR
6	response to organic substance	GO:0010033	9.86	IL10 TGFB1 TNF
7	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.86	IL1B IL6 TGFB1 TNF
8	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.85	IL6 TGFB1 TNF
9	cellular response to organic cyclic compound	GO:0071407	9.83	IL1B TGFB1 TNF
10	response to glucocorticoid	GO:0051384	9.83	IL10 IL6 TNF
11	positive regulation of DNA binding transcription factor activity	GO:0051091	9.83	IL10 IL1B IL6 TNF
12	positive regulation of protein phosphorylation	GO:0001934	9.83	IL1B IL2 NKX3-1 TGFB1 TNF
13	positive regulation of T cell proliferation	GO:0042102	9.82	IL1B IL2 IL6
14	positive regulation of interleukin-6 production	GO:0032755	9.79	IL1B IL6 TNF
15	positive regulation of cell division	GO:0051781	9.78	IL1B NKX3-1 TGFB1
16	negative regulation of fat cell differentiation	GO:0045599	9.77	IL6 TGFB1 TNF
17	positive regulation of interferon-gamma production	GO:0032729	9.77	IL1B IL2 TNF
18	lipopolysaccharide-mediated signaling pathway	GO:0031663	9.72	IL1B TGFB1 TNF
19	cellular response to lipopolysaccharide	GO:0071222	9.72	CXCL8 IL10 IL6 TNF VDR
20	positive regulation of chemokine production	GO:0032722	9.71	IL6 TNF
21	positive regulation of histone acetylation	GO:0035066	9.71	IL1B TGFB1
22	embryonic digestive tract development	GO:0048566	9.7	CXCL8 TNF
23	negative regulation of lipid catabolic process	GO:0050995	9.7	IL1B TNF
24	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	9.7	IL1B TNF
25	regulation of regulatory T cell differentiation	GO:0045589	9.7	IL2 TGFB1
26	regulation of signaling receptor activity	GO:0010469	9.7	CXCL8 IL10 IL1B IL2 IL6 TGFB1
27	negative regulation of growth of symbiont in host	GO:0044130	9.69	IL10 TNF
28	response to molecule of bacterial origin	GO:0002237	9.69	CXCL8 IL10
29	positive regulation of interleukin-17 production	GO:0032740	9.69	IL2 TGFB1
30	positive regulation of immunoglobulin secretion	GO:0051024	9.68	IL2 IL6
31	positive regulation of regulatory T cell differentiation	GO:0045591	9.68	IL2 TGFB1
32	negative regulation of lipid storage	GO:0010888	9.67	IL6 TNF
33	positive regulation of chemokine biosynthetic process	GO:0045080	9.67	IL1B TNF
34	positive regulation of heterotypic cell-cell adhesion	GO:0034116	9.67	IL10 IL1B TNF
35	protein kinase B signaling	GO:0043491	9.67	IL1B NKX3-1 TGFB1 TNF
36	endothelial cell apoptotic process	GO:0072577	9.66	IL10 TNF
37	regulation of establishment of endothelial barrier	GO:1903140	9.65	IL1B TNF
38	negative regulation of cytokine secretion involved in immune response	GO:0002740	9.64	IL10 TNF
39	positive regulation of fever generation	GO:0031622	9.63	IL1B TNF
40	epithelial cell proliferation involved in salivary gland morphogenesis	GO:0060664	9.62	NKX3-1 TNF
41	sequestering of triglyceride	GO:0030730	9.61	IL1B TNF
42	receptor biosynthetic process	GO:0032800	9.58	IL10 TNF
43	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.58	IL1B TNF
44	positive regulation of mononuclear cell migration	GO:0071677	9.57	TGFB1 TNF
45	negative regulation of mitotic cell cycle	GO:0045930	9.56	IL10 NKX3-1 TGFB1 TNF
46	cytokine-mediated signaling pathway	GO:0019221	9.5	CXCL8 IL10 IL1B IL2 IL6 TGFB1
47	negative regulation of cell proliferation	GO:0008285	9.23	ADRA1A CXCL8 IL10 IL1B IL6 NKX3-1
48	positive regulation of cell proliferation	GO:0008284	10.04	IL1B IL2 IL6 NKX3-1 TGFB1
49	positive regulation of transcription, DNA-templated	GO:0045893	10.01	IL10 IL1B IL6 NKX3-1 TGFB1 TNF
50	positive regulation of transcription by RNA polymerase II	GO:0045944	10.01	IL10 IL1B IL2 IL6 NKX3-1 TGFB1

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.26	IL10 IL2 IL6 TGFB1
2	cytokine activity	GO:0005125	9.17	CXCL8 IL10 IL1B IL2 IL6 TGFB1

Sources

Sources for Prostatitis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Prostatitis

Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Classifications:

External Ids:

Summaries for Prostatitis

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Prostatitis:

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Prostatitis:

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

Publications for Prostatitis

Articles related to Prostatitis:

Genes for Prostatitis

Genes related to Prostatitis (0 elite genes):

Variations for Prostatitis

Expression for Prostatitis

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

Sources for Prostatitis

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :